80 related articles for article (PubMed ID: 854865)
21. Effect of 1,6-dibromodulcitol (DBD) on the RNA metabolism of S37 tumour cells.
Kiss J; Kopper L; Lapis K
Acta Biol Acad Sci Hung; 1973; 24(3):131-5. PubMed ID: 4793382
[No Abstract] [Full Text] [Related]
22. Evaluation of mitolactol in women with advanced breast cancer and prior chemotherapy exposure.
Ingle JN; Brunk SF; Krook JE; Everson LK; Green SJ; Kvols LK; Etzell PS
Cancer Treat Rep; 1983 Oct; 67(10):955-6. PubMed ID: 6627238
[No Abstract] [Full Text] [Related]
23. Phase II evaluation of mitolactol in squamous cell carcinoma of the head and neck: a Southeastern Cancer Study Group Trial.
McHale MS; Velez-Garcia E; Nelson O; Williams SD; Maddox W; Birch R
Cancer Treat Rep; 1986 Jul; 70(7):925-6. PubMed ID: 3521849
[No Abstract] [Full Text] [Related]
24. Mitolactol chemotherapy for malignant melanoma: a phase II study.
Malden LT; Coates AS; Milton GW; McCarthy WH; Levi JA; Woods RL; Byrne MJ; Reynolds PM; Fox RM; Hedley DW
Cancer Treat Rep; 1984; 68(7-8):1045-6. PubMed ID: 6744338
[TBL] [Abstract][Full Text] [Related]
25. Phase II trial of mitolactol in patients with metastatic melanoma.
Medina W; Kirkwood JM
Cancer Treat Rep; 1982 Jan; 66(1):195-6. PubMed ID: 7053257
[No Abstract] [Full Text] [Related]
26. Forms and results of mitolactol therapy.
Hindy I; Szántó J; Bodrogi I; Farkas E; Eckhardt S
Oncology; 1980; 37 Suppl 1():115-7. PubMed ID: 6935577
[TBL] [Abstract][Full Text] [Related]
27. [Value of mitolactol in palliative treatment of various malignant tumors].
Wiernik-Strzeszyńska E; Pawlicki M
Nowotwory; 1980; 30(3):271-6. PubMed ID: 6159601
[No Abstract] [Full Text] [Related]
28. Histological examination of combined effects of chemotherapeutic agents and differently fractionated irradiations in transplanted solid Ehrlich carcinoma of mice. II. Observations after dibromodulcitol treatment.
Unger E
Strahlenther Onkol; 1987 Aug; 163(8):557-60. PubMed ID: 3629470
[TBL] [Abstract][Full Text] [Related]
29. Activity of mitolactol in cancer of the uterine cervix.
Lira-Puerto V; Morales-Canfield F; Wernz J; Muggia FM
Cancer Treat Rep; 1984 Apr; 68(4):669-70. PubMed ID: 6713421
[TBL] [Abstract][Full Text] [Related]
30. Dibromodulcitol in the treatment of metastatic hemangiopericytoma.
Conroy JF; Roda PI; Prasasvinichai S
Am J Clin Oncol; 1982 Aug; 5(4):453-6. PubMed ID: 7113966
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of an intermittent schedule of mitolactol in advanced non-small cell lung cancer.
Eagan RT; Frytak S; Nichols WC; Ingle JN; Creagan ET; Kvols LK; Coles DT
Cancer Treat Rep; 1981; 65(11-12):1099-1101. PubMed ID: 6271397
[No Abstract] [Full Text] [Related]
32. Metabolism and pharmacokinetics of dibromodulcitol (DBD, NSC-104800) in man. I. Metabolites of DBD.
Horváth IP; Csetényi J; Kerpel-Fronius S; Hindy I; Eckhardt S
Eur J Cancer (1965); 1979 Mar; 15(3):337-44. PubMed ID: 446515
[No Abstract] [Full Text] [Related]
33. Cytochemical characterization of Yoshida sarcoma cells resistant to dibromodulcitol.
Gáti E; Pokorny E; Somfai-Relle S; Szentirmay Z
Int J Tissue React; 1984; 6(1):43-51. PubMed ID: 6715118
[TBL] [Abstract][Full Text] [Related]
34. Phase II trial of mitolactol in previously treated and untreated patients with advanced colorectal cancer: an Illinois Cancer Council trial.
Locker GY; Lanzotti V; Sweet D; Lad T; Khandekar J; Stiff P; Johnson C; Miller S
Cancer Treat Rep; 1984 Oct; 68(10):1303-4. PubMed ID: 6525605
[No Abstract] [Full Text] [Related]
35. Phase II study of mitolactol in chemotherapy-refractory metastatic breast cancer.
Creech RH; Catalano RB; Dierks KM; Shah MK
Cancer Treat Rep; 1984 Dec; 68(12):1499-501. PubMed ID: 6548936
[TBL] [Abstract][Full Text] [Related]
36. Potentiation of BCNU-induced cytotoxicity and sister chromatid exchanges by dibromodulcitol in vitro.
Pulst SM; Deen DF
Anticancer Res; 1990; 10(6):1647-50. PubMed ID: 2285238
[TBL] [Abstract][Full Text] [Related]
37. [Pharmacokinetic study of dibromodulcitol in children with brain tumors].
Paál K; Erdélyi-Tóth V; Pap E; Csáki C; Ferencz T; Schuler D; Borsi J
Orv Hetil; 1994 Nov; 135(46):2527-34. PubMed ID: 7800388
[TBL] [Abstract][Full Text] [Related]
38. Phase II study of mitolactol in metastatic malignant melanoma.
Simmonds MA; Lipton A; Harvey HA; Ellison N; White DS
Cancer Treat Rep; 1985 Jan; 69(1):65-7. PubMed ID: 3967260
[TBL] [Abstract][Full Text] [Related]
39. Phase II study of mitolactol and semustine combination chemotherapy for advanced malignant melanoma.
Creagan ET; Ahmann DL; Schutt AJ; Green SJ
Cancer Treat Rep; 1982 Jun; 66(6):1425-6. PubMed ID: 7083244
[TBL] [Abstract][Full Text] [Related]
40. The distribution of [3H]-dibromodulcitol in the central nervous system of patients with brain tumour.
Csetényi J; Afra D; Kerpel-Fronius S; Horváth IP; Institoris L; Eckhardt S
Eur J Cancer Clin Oncol; 1983 Oct; 19(10):1389-92. PubMed ID: 6685628
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
